RxDoctor Payments Data

Stephen Bardot, MD

Urology · New Orleans, LANPI 1942267521

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.1% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Boston Scientific at 29.6% of the total. Reporting peaked in 2023 at $671 and has fallen 63.4% since, to $245 in 2025. That places this record below the midpoint for urology clinicians in LA, where the typical reported total is $2,723.

$1,269in general payments, 2019–2025

Across 22 payments — averaging $57.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$376
  • Kerecis Limited$172
  • Cook Medical LLC$168
  • Myriad Genetic Laboratories, Inc.$165
  • KARL Storz Endoscopy-america$150
  • Astellas Pharma US Inc$100
  • plus $138 from 3 others
$570,991in research payments, 2019–2025

Across 43 payments — averaging $13,279 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$453K
  • Janssen Research & Development, LLC$118K

What the payments were for

  • Food & beverage$1,16992%
  • Education$1008%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,269 in reported general payments places this provider in the 30th percentile of 199 urology providers in Louisiana.

See all urology providers in Louisiana

Medicare billing

Part B allowed, 2024
$56,502
Medicare patients
204
Services billed
463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl122$1,212
Dutasteride19$714
Finasteride27$347
Alfuzosin Hcl ErAlfuzosin Hcl12$222
Tadalafil13$206
Oxybutynin Chloride ErOxybutynin Chloride14$138
Ciprofloxacin Hcl71$82

Paid to pharmacies, not to this prescriber.

Other urology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →